Digestive Health

Investigators found significant associations between GI-PACS and multi-system concomitant symptoms.

Patients with diabetes taking a GLP-1 RA of any type had an increased risk of a new GERD diagnosis.

Anti-TNF agents were found to increase the risk of autoimmune disease, especially in psoriasis and lupus.

Vonoprazan appeared to be cost saving below a threshold price of $8.57 per pill.

A study presented at Digestive Disease Week 2023 compared the effectiveness of different approaches to prevent complications in individuals with the common disease.

Hesitation from patients and providers to switch to an infliximab biosimilar may not be necessary, new study finds.

The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.

Researchers found a significant decrease in mortality or discharge to hospice with the hydrocortisone-fludrocortisone combination versus hydrocortisone alone in septic shock cases.

The drug is a rare FDA-approved liquid formulation that treats ulcers and lowers risk of gastrointestinal bleeding in chronically ill patients.

Prevalence of IBD doubled between 1995 and 2016 and exposure to antibiotics may be to blame.

There are no currently approved medications for the treatment of NASH.

Successful clinical trials for digestive health treatments may soon yield approvals.

New research indicates that gay men are at increased risk of inflammatory bowel disease.

New research illustrates the efficacy of upadacitinib for treating Crohn's and ulcerative colitis.

Clinical trial results reported at United European Gastroenterology Week 2022 highlight Stelara's effectiveness.

Technlogy could greatly improve drug absorption.

FDA approves durvalumab to treat biliary tract cancer in combination with chemotherapy.

New research adds further evidence that early in life antibiotic exposure can have lifelong impact.

This new treatment option copackages 3 drugs for optimal treatment.

New research examines how often immune-mediated inflammatory skin diseases occur in patients with inflammatory bowel disease.

Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.

The American Gastroenterological Association has released updated guidelines for treating irritable bowel syndrome with constipation (IBS-C).

Treatments, including some biosimilars, may soon be offering relief to patients.

Pharmacists who encounter patients with severe gastrointestinal complains may want to stay abreast of ongoing issues with the meal delivery service.

New options are being developed for conditions including psoriatic arthritis, ulcerative colitis, and asthma.

High-dose haloperidol and aprepitant were both associated with emergency department discharge.

Seniors prescribed multiple courses of antibiotics were at greater risk for IBD.

Patients taking high-risk antibiotics and a probiotic capsule had a lower risk of healthcare-associated C diff infections.

Reducing perioperative antibiotic use can mitigate this risk.